Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, Kalkine Media, CancerNetwork and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 53d ago.
Quick answers
Why is "Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC Yahoo Finance · 55d ago
- Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? Kalkine Media · 55d ago
- Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial CancerNetwork · 55d ago
- Pfizer drug acquired in Seagen deal disappoints in lung cancer study BioPharma Dive · 55d ago
- Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC OncLive · 55d ago
- Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial Endpoints News · 55d ago
Topics
Related trends
Ask An Expert: What You Need to Know About Lung Cancer Testing
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
How Pfizer Offset A 95% Decline For One Of Its Drugs
Pfizer has adjusted its 2026 revenue guidance upward following the release of its second-quarter financial results.
Why Pfizer Just Hiked Its Guidance By $500 Million
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.
Pfizer's stock is rising after beating earnings estimates, despite a 95% plunge in revenue from its Covid pill.
Modular in vivo antibody–ADC click to reverse drug resistance in tumours
A new modular in vivo antibody-ADC click chemistry approach aims to reverse drug resistance in tumors, including pancreatic cancer.
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
AstraZeneca shares dropped six percent following a heart drug trial setback that simultaneously boosted rival stocks.